Literature DB >> 1589694

Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.

C A Yedema1, P Kenemans, T Wobbes, C M Thomas, G G Bon, C Mulder, F J Voorhorst, A A Verstraeten, G J van Kamp, J Hilgers.   

Abstract

In the search for a method to facilitate the preoperative discrimination of ovarian carcinomas from colorectal carcinomas serum levels of 6 tumor markers were measured in 47 patients presenting with ovarian cancer and compared to levels found in 24 female patients with advanced, untreated colorectal cancer. The markers studied were CA 125, CA 15.3, CA 19.9, CEA and two recently developed mucin markers, CA M29 and CA M26. Levels of CA 125, CA 15.3, CEA and CA M29 showed significant differences between both groups. In predicting ovarian cancer, sensitivity was highest for CA 125 at 94% (35 U/ml cutoff level). However, the specificity of CA 125 was at 71% low. Specificity increased significantly by using a combination of a CA 125-positive score (greater than 35 U/ml) and a simultaneous negative CEA score (less than or equal to 5 ng/ml) (specificity 100%, sensitivity 81%). A CA 125/CEA serum ratio greater than 25 resulted in the highest discriminative power with a specificity of 100% and a sensitivity of 91% resulting in an overall test accuracy of 94%. It is concluded that the serum tumor markers used, especially a combination of CA 125 and CEA, are helpful in the preoperative differential diagnosis between adenocarcinomas of ovarian and colorectal origin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589694     DOI: 10.1159/000217748

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

Review 1.  CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know-Radiology In Training.

Authors:  Maria Clara Fernandes; Ines Nikolovski; Kara Long Roche; Yulia Lakhman
Journal:  Radiology       Date:  2022-05-24       Impact factor: 29.146

2.  Metastatic Tumors to the Ovary-a Surgeon's Dilemma.

Authors:  Ramesan C K; Vinotha Thomas; Dhanya Susan Thomas; Sherin Daniel; Ajit Sebastian; Anitha Thomas; Rachel George Chandy; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2021-01-07

3.  The diagnosis and outcome of Krukenberg tumors.

Authors:  Hao Xie; Bradley J Erickson; Shannon P Sheedy; Jun Yin; Joleen M Hubbard
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  A case report of appendiceal adenocarcinoma without gastrointestinal evidence mimicking primary ovarian cancer.

Authors:  Chih-Wei Lin; Shu-Ling Peng; Shu-Hsien Wang; Pei-Ying Wu
Journal:  J Int Med Res       Date:  2022-04       Impact factor: 1.671

Review 5.  The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.

Authors:  Ondřej Kubeček; Jan Laco; Jiří Špaček; Jiří Petera; Jindřich Kopecký; Alena Kubečková; Stanislav Filip
Journal:  Clin Exp Metastasis       Date:  2017-07-20       Impact factor: 5.150

Review 6.  High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers.

Authors:  Jung-Hyun Rho; Paul D Lampe
Journal:  Proteomes       Date:  2014-01-13

7.  Diagnosis efficacy of CEUS for hepatic inflammatory lesions.

Authors:  Yuanyuan Guo; Xiachuan Qin; Shaoxian Chen; Xuebin Liu; Peng Gu
Journal:  J Clin Lab Anal       Date:  2020-02-03       Impact factor: 2.352

8.  Isolated Ovarian Metastasis from Pancreatic Cancer Mimicking Primary Ovarian Neoplasia: Role of Molecular Analysis in Determining Diagnosis.

Authors:  Catherine M Tucker; Cheryl L Godcharles; Wei Jiang; Charles J Yeo; Norman G Rosenblum; Ethan J Halpern; William E Luginbuhl; Anthony J Prestipino
Journal:  J Pancreat Cancer       Date:  2021-10-14

9.  Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement-A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO.

Authors:  Leila Bengrine; Naoual Bakrin; Frédérique Rousseau; Vincent Lavoué; Claire Falandry
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.